Clinical Trial Update: MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating MV-NIS infected mesenchymal stem cells for recurrent ovarian, primary peritoneal, or fallopian tube cancer. Results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• MV-NIS infected mesenchymal stem cells

Snippet

Sponsor: Mayo Clinic | Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-16